Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)
Key facts
- Who runs it
- National Institute of Allergy and Infectious Diseases (NIAID)
- Where
- Atlanta, Boston, and Rochester, United StatesSee the 3 sites
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 8 people enrolled
- Started
- 13 Oct 2021
- Ended
- 4 Jan 2024
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- elotuzumab
- placebo for elotuzumab
- methylprednisolone
- diphenhydramine
- acetaminophen
- famotidine
- prednisone
- Record updated
- 5 February 2026
- Why it stopped
- The study was terminated early based on disease flare/lack of efficacy in the early phase of the trial.
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 28 criteriaShow less
Who can take part
- Individuals who meet all of the following criteria are eligible for enrollment as study participants:
- Participant must be able to understand and provide informed consent and be willing to comply with study procedures and follow up
- Are at least 18 years of age and not older than 70 years of age at screening
- Meet the ACR/EULAR Classification Criteria for IgG4-RD [30, 31]
- Have active disease based at screening on an IgG4-RD RI ≥4, with disease manifestations in at least two organ systems
- May have newly-diagnosed or relapsing disease at screening. Relapsing disease is defined as IgG4-RD that has previously been in remission but is now active again
- May be on treatment or off treatment for IgG4-RD at the time of screening. If on treatment, must be willing to discontinue those other treatments before the baseline visit
- No history of severe allergic reactions to monoclonal antibodies
- Female participants of childbearing potential must have a negative pregnancy test upon study entry
- Female participants of childbearing potential and male participants with a partner of childbearing potential must agree to consistently and correctly use FDA approved highly effective methods of birth control for the entire duration of the study and 6 months after last elotuzumab infusion
- Immunization with one of the FDA authorized or licensed SARS-CoV-2 vaccines as per CDC recommendations at the time of informed consent is required for study entry. Vaccinations must have been completed at least 2 weeks prior to start of study therapy
Who cannot take part
- Active infection requiring hospitalization or treatment with systemic antimicrobial agents within the 30 days prior to treatment allocation/randomization
- Prior use of rituximab or other B cell depleting agents within 9 months of enrollment unless B cells have been demonstrated to have repopulated
- Use of any investigational agent or biologic and non-biologic DMARDs within 5 half-lives of the agent (or 6 months if the half-life is unknown) prior to enrollment
- At or within 90 days of screening: Positive Interferon-Gamma Release Assay (IGRA). Indeterminate IGRAs must be repeated (with same or other IGRA per local policy) and shown to be negative. Alternatively, if the assay remains indeterminant, a participant must have a negative PPD. Finally, if the participant has had the Bacille Calmette-Guerin (BCG) vaccine or has some other condition complicating the interpretation of TB testing, consultation with infectious disease specialist must be obtained before receipt of the first investigational infusion; Participants diagnosed with latent TB are eligible but must have received appropriate prophylaxis for 30 days before their first investigational infusion
- Live vaccines within 8 weeks of initiating study therapy
- Evidence a SARS-CoV-2 (COVID-19) infection started within the 30 days prior to treatment allocation/randomization. Participants diagnosed with SARS-CoV-2 (COVID-19) infection more than 30 days prior to treatment allocation/randomization must have symptoms resolved and be deemed fit to participate in the trial
- Presence of a condition other than IgG4-RD that (e.g., asthma) is likely to require systemic Glucocorticoids (GC) for disease control during the period of the trial
- Malignancy within 5 years (except successfully treated in situ cervical cancer, resected squamous cell or basal cell carcinoma of the skin.)
- Evidence of another uncontrolled condition which, in the judgment of the investigator, could interfere with participation in the trial according to the protocol
- Medical history or serologic evidence at Screening of chronic infections including:; Human immunodeficiency virus infection; Hepatitis B as indicated by surface antigen or hepatitis B core antibody positivity; Hepatitis C as indicated by anti-hepatitis C antibody positivity; if a participant is Hepatitis C antibody positive, they will be eligible to participate in the study if he/she is negative for viral load at Screening
- Substance use disorder, including the recurrent use of alcohol and/or drugs within the past year associated with clinically significant impairment associated with failure to meet major responsibilities at work, school, or home
- IgG4-RD that is dominated primarily by advanced fibrotic lesions. Specifically, participants whose disease manifestations consist only of; retroperitoneal fibrosis,; fibrosing mediatinitis,; sclerosing mesenteritis, or; Riedel's thyroiditis. Participants with these disease manifestations can be included, however, only if they have disease in 2 organ systems that is not of an advanced fibrotic nature and otherwise meet the Inclusion and Exclusion Criteria
- The following lab values as indicators of hepatic dysfunction:; Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than three times the upper limit of normal (ULN); Total bilirubin > two times the ULN unless caused by Gilbert's disease. Gilbert's disease with total bilirubin > three times ULN; Serum albumin < 2.5 gm/dL
- Any of the following laboratory tests at the Screening Visit:; White blood cell count (WBC) < 3.0 x 103/µL; Absolute neutrophil count (ANC) < 1.5 x 103/µL; Hemoglobin < 10 g/dL; Platelet count < 75 x 109/L; Estimated glomerular filtration rate (eGFR) ≤ 45 ml/minute/1.73 m2
- Individuals who meet any of these criteria are not eligible for enrollment as study participants:
- The use of supplemental oxygen at baseline
- Participant is pregnant or breastfeeding, or planning a pregnancy while enrolled in the study
Where in United States
- Emory HealthcareAtlanta, United States
- Massachusetts General HospitalBoston, United States
- Mayo Clinic: Pulmonary and Critical Care MedicineRochester, United States
About the trial
What the trial wants to find out
This is a two-part multi-center clinical trial in participants with active IgG4-RD.
Read full original descriptionShow less
Part 1 (Cohort 1a and Cohort 1B) is an open-label, dose escalation phase to determine the safety of elotuzumab for investigation in IgG4-RD.
Part 2 (Cohort 2) is a randomized, placebo-controlled, double-blinded (masked) trial phase to compare the effects of elotuzumab and prednisone to elotuzumab placebo and prednisone in participants with IgG4 RD.
Approximately 75 participants with active IgG4-RD will be enrolled in the overall program, 12 in Part 1 and 63 in Part 2. Randomization in Part 2: 2 to 1, with approximately forty-two participants randomized to elotuzumab plus prednisone taper, and twenty-one participants randomized to placebo for elotuzumab plus prednisone taper.
The total duration of participation for each participant in this trial will be 48 weeks (11 months).
The 4 groups in the trial
- Cohort 1a: Elotuzumab-One-Month Regimen (Open-Label) + Pred TaperTreatment being tested
Per protocol: Six participants will receive elotuzumab on days 0,7, 14, 21, and the prescribed 10-week prednisone taper. * Elotuzumab: 10 mg/kg administered once weekly, intravenously for 4 doses, per protocol. * Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 (baseline) that is taken orally (by mouth) daily, per protocol. Dosage in milligrams (mgs).
Treatment: elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine, and prednisone
- Cohort 1b: Elotuzumab-Twelve-Month Regimen (Open-Label) + Pred TaperTreatment being tested
Per protocol: Six participants will receive elotuzumab over a 48 week period, dose of 10mg/kg IV x 1, at baseline, then at weeks 8, 16, 24, 32 and 40 (for a total of 6 doses), with the prescribed 10-week prednisone taper. * Elotuzumab: 10 mg/kg administered as referenced above, intravenously, per protocol. * Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 (baseline) that is taken orally (by mouth) daily, per protocol. Dosage in milligrams (mgs).
Treatment: elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine, and prednisone
- Cohort 2: Arm A- Elotuzumab (Randomized) + Pred TaperTreatment being tested
Safety and efficacy analyses from Cohort 1a and Cohort 1b will occur prior to initiating Cohort 2 (Randomized). Assuming no safety signal for Cohort 1, forty-two participants will receive elotuzumab per the regimen prescribed above in Part 1B, with the prescribed 10-week prednisone taper. * Elotuzumab: 10 mg/kg administered as referenced above, intravenously, per protocol. * Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 that is taken daily by mouth, per protocol. Dosage in milligrams (mgs).
Treatment: elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine, and prednisone
- Cohort 2: Arm B-Placebo (Randomized) + Pred TaperPlacebo, for comparison
Safety and efficacy analyses from Cohort 1a and Cohort 1b will occur prior to initiating Cohort 2 (Randomized). Twenty-one participants will receive placebo for elotuzumab on day 0, then weeks 8, 16, 24, 32 and 40, and the prescribed 10-week prednisone taper. * Placebo for elotuzumab: Administered on same schedule as elotuzumab described in Cohort 2 Arm A: intravenously, per protocol. * Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 taken daily by mouth, per protocol. Dosage in milligrams (mgs).
Treatment: placebo for elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine, and prednisone
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 5 February 2026